Aequus Pharmaceuticals Mutual Funds | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Aequus Pharmaceuticals Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Front Street Hedge Fund

0

0%

-375,000

0%

06/30/2017

About Aequus Pharmaceuticals

View Profile

Address	200 Granville Street Vancouver British Columbia V6C 1S4 Canada
Employees	-
Website	http://www.aequuspharma.ca
Updated	07/08/2019
Aequus Pharmaceuticals, Inc. focuses on the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.